0001193125-21-093409.txt : 20210325 0001193125-21-093409.hdr.sgml : 20210325 20210325074155 ACCESSION NUMBER: 0001193125-21-093409 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210323 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210325 DATE AS OF CHANGE: 20210325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AstroNova, Inc. CENTRAL INDEX KEY: 0000008146 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 050318215 STATE OF INCORPORATION: RI FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13200 FILM NUMBER: 21770125 BUSINESS ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 BUSINESS PHONE: 4018284000 MAIL ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 FORMER COMPANY: FORMER CONFORMED NAME: ASTRO MED INC /NEW/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ATLAN TOL INDUSTRIES INC DATE OF NAME CHANGE: 19850220 8-K 1 d69755d8k.htm 8-K 8-K
false 0000008146 0000008146 2021-03-23 2021-03-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 23, 2021

 

 

ASTRONOVA, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Rhode Island   0-13200   05-0318215
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

600 East Greenwich Avenue
West Warwick, RI 02893
(Address of principal executive offices) (Zip Code)

(401) 828-4000

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading

Symbol(s)

 

Name of Each Exchange

on which Registered

Common Stock, $0.05 Par Value   ALOT   NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 1.01

Entry into a Material Definitive Agreement.

The information set forth in Item 2.03 below is incorporated herein by reference.

 

Item 2.02

Results of Operations and Financial Condition.

On March 25, 2021, AstroNova, Inc. (the “Company”) issued a press release reporting the financial results for its fiscal fourth quarter and year ended January 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in Item 2.02 of this report and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On March 24, 2021, the Company entered into a First Amendment to Credit Agreement (the “Amendment”) to its Amended and Restated Credit Agreement dated as of July 30, 2020 (the “Existing Credit Agreement”; the Existing Credit Agreement amended by the Amendment, the “Amended Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), and the Company’s subsidiaries ANI ApS and TrojanLabel ApS. Immediately prior to the closing of the Amendment, the Company repaid $2,576,000 in principal amount of the term loan outstanding and borrowed by it under the Existing Credit Agreement, the resulting outstanding balance of the term loan was $10,000,000, and the Company had no amount drawn and outstanding under the revolving credit facility under the Existing Credit Agreement.

The Amended Credit Agreement provides for (i) a term loan to the Company in the principal amount of $10,000,000, and (ii) a $22,500,000 revolving credit facility available to the Company for general corporate purposes. At the closing of the Amendment , the Company borrowed the entire $10,000,000 term loan to refinance the outstanding term loan under the Existing Credit Agreement; no amount was borrowed under the revolving credit facility.

Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at the Company’s option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.

The Amended Credit Agreement requires that the term loan be paid in quarterly installments on the last day of each fiscal quarter of the Company over the term of the Amended Credit Agreement on the following repayment schedule: the principal amount of each quarterly installment required to be paid on the last day of each of the Company’s fiscal quarters ending on or about April 30, 2021 through January 31, 2022 is $187,500; the principal amount of each quarterly installment required to be paid on the last day of each of the Company’s fiscal quarters ending on or about April 30, 2022 through January 31, 2023 is $250,000; the principal amount of each quarterly installment required to be paid on the last day of each of the Company’s fiscal

 

2


quarters ending on or about April 30, 2023 through January 31, 2025 is $312,500; the principal amount of each quarterly installment required to be paid on the last day of each of the Company’s fiscal quarters ending on or about April 30, 2025 and July 31, 2025 is $500,000; and the entire remaining principal balance of the term loan is required to be paid on September 30, 2025. The Company may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). The Company may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than September 30, 2025, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. The Company may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.

The Amended Credit Agreement includes an uncommitted accordion provision under which the term loan and/or revolving credit facility commitments thereunder may be increased in an aggregate principal amount not exceeding $10,000,000, subject to the Company’s obtaining the agreement of the Lender and the satisfaction of certain other conditions.

As under the Existing Credit Agreement, the loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.

Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.

The interest rates under the Existing Credit Agreement were modified in the Amended Credit Agreement as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at the Company’s option, either (a) the LIBOR Rate as defined in the Amended Credit Agreement (or, in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.30% based on the Company’s consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00%, or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.30% based on the Company’s consolidated leverage ratio. In addition to certain other fees and expenses that the Company is required to pay to the Lender, the Company is required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.30% based on the Company’s consolidated leverage ratio.

The Company must comply with various customary financial and non-financial covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. The minimum EBITDA, minimum consolidated asset coverage ratio, minimum liquidity and maximum capital expenditures covenants with which the

 

3


Company was required to comply under the Existing Credit Agreement were eliminated by the Amendment. The primary non-financial covenants limit the Company’s and its subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Amendment.

The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of the Company’s covenants or representations under the loan documents, default under any other of the Company’s or its subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to the Company or any of its subsidiaries, a significant unsatisfied judgment against the Company or any of its subsidiaries, or a change of control of the Company.

The Company’s obligations under the Amended Credit Agreement continue to be secured by substantially all of the personal property assets of the Company (including a pledge of the equity interests held by the Company in its subsidiaries ANI ApS, AstroNova GmbH AstroNova SAS), subject to certain exceptions, and by a mortgage on the Company’s owned real property in West Warwick, Rhode Island. Pursuant to the Amendment, the guarantees of the Company’s obligations under the Existing Credit Agreement that were previously provided by ANI ApS and TrojanLabel ApS were released.

 

Item 8.01

Other Items.

On March 23, 2021, the Company’s Board of Directors fixed June 8, 2021 as the date of the Company’s 2021 annual meeting of shareholders (the “Annual Meeting”). The record date for the Annual Meeting will be April 9, 2021. Further details regarding the Annual Meeting will appear in the Company’s 2021 proxy statement.

 

Item 9.01

Financial Statement and Exhibits.

 

(d)

Exhibits

 

Exhibit
No.

  

Exhibit

99.1    Press Release dated March 25, 2021

 

4


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ASTRONOVA, INC.
Dated: March 25, 2021     By:  

/s/ David S. Smith

      David S. Smith
      Vice President, Chief Financial Officer and Treasurer

 

5

EX-99.1 2 d69755dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

AstroNova Reports Fiscal Fourth-Quarter and Full-Year 2021

Financial Results

Product Identification Segment Posts Record Revenue and Profits

Fiscal Fourth-Quarter 2021 Financial Summary

 

   

Bookings of $29.2 million

 

   

Backlog at quarter end of $22.5 million

 

   

Revenue of $29.4 million

 

   

Operating income of $1.1 million

 

   

Net income of $0.8 million, or $0.12 per diluted share

 

   

Adjusted EBITDA of $3.1 million, or 10.7% of revenue

Fiscal Full-Year 2021 Financial Summary

 

   

Bookings of $113.6 million

 

   

Revenue of $116.0 million

 

   

Operating income of $2.4 million

 

   

Net income of $1.3 million, or $0.18 per diluted share

 

   

Adjusted EBITDA of $10.9 million, or 9.4% of revenue

WEST WARWICK, R.I. — March 25, 2021 — AstroNova, Inc. (NASDAQ: ALOT), a global leader in data visualization technologies, today announced financial results for the fiscal fourth quarter and full year ended January 31, 2021.

“Our Product Identification segment performed extremely well in fiscal 2021, which marked the segment’s eighth consecutive year of revenue growth,” said Greg Woods, AstroNova’s President and Chief Executive Officer. “In the fourth quarter Product Identification achieved 13.2 percent top-line growth compared to the same quarter last year and posted a record segment operating profit margin for the full year of 14.3 percent. Also in the quarter, we posted the highest number of color printer shipments in more than two years, boosted by a growing response to our enhanced digital marketing initiatives and a strong uptake of new products such as our T3-OPX overprinting solution. Consistent with our recurring revenue model, hardware demand is a leading indicator of demand for our supplies and services.

“In our Test & Measurement segment, our fourth-quarter results continued to be hampered by the effects of the COVID-19 pandemic and the 737 MAX grounding on the aerospace industry,” Woods said.

 

1


“But with the MAX’s recent return to service and positive news on the vaccine front, we are hopeful that the sequential revenue improvement we saw in our Test & Measurement segment in the fourth quarter marks the early signs of a recovery for the aerospace industry.

“From a geographic standpoint, international revenue grew to 44 percent of total revenue in the fourth quarter from 37 percent in the same period a year earlier,” Woods said. “We saw particular strength in EMEA, where we recently enhanced our marketing team. In addition, we are expanding our presence in China with the opening of a second location, in the southern port city of Guangzhou, complementing our location in Shanghai’s Pilot Free Trade Zone.

“We navigated a challenging fiscal 2021 by focusing on the things within our control. Our first priority was protecting our team by deploying comprehensive global COVID-19 safety measures. Additionally, we moved quickly to realign our workforce, reduce costs and increase liquidity to ensure that we continued to make progress on our long-term strategic growth initiatives, including our innovation investments. As a result, we had no serious COVID-19-related illnesses among our global team; all our facilities remained open and operational; and—despite a $17.4 million aerospace-driven decline in revenue—we posted a full-year operating profit equal to fiscal 2020 and increased Adjusted EBITDA. We remain on pace to launch at least one major product each year, coupled with a range of technology innovations and ancillary products,” Woods concluded.

AstroNova Signs New Credit Agreement

On March 24, 2021, the Company entered into an amendment to the credit agreement with its current lender that provides for a term loan of $10 million and a revolving credit facility of $22.5 million, both expiring on September 30, 2025. In addition, the agreement provides, subject to satisfying certain lender conditions, for an uncommitted accordion provision of up to $10 million. At the closing of the agreement, AstroNova lowered its outstanding bank term loan debt to $10 million, a reduction of $2.6 million from January 31, 2021, with no amounts outstanding under the revolving credit facility.

“The terms of our new credit agreement, including material increases in available credit, extended tenor, improved covenant and pricing terms, and reduced amortization requirements, reflect the operating performance improvements we have achieved in response to the recent market headwinds,” said David Smith, AstroNova’s Chief Financial Officer. “The new agreement supports both our near-to-medium term liquidity requirements and growth objectives.”

Fiscal Q4 2021 Operating Segment Results

Product Identification segment revenue was $23.4 million, compared with $20.6 million in the prior-year period. Segment operating income was $3.1 million, or 13.2% of revenue, compared with $0.5 million, or 2.5% of revenue, in the prior year, reflecting higher revenue, increased efficiencies and reductions in operating costs.

Test & Measurement segment revenue was $6.1 million, compared with $9.8 million in the same period of fiscal 2020, due to the continued grounding of the Boeing 737 MAX and demand falloff in the aerospace industry related to COVID-19. The Test & Measurement segment recorded an operating profit of $0.3 million, or 4.6% of revenue, compared with segment operating income of $0.7 million, or 7.6% of revenue, in the comparable period of fiscal 2020, a direct result of declines in aerospace printer sales and adverse mix, despite lower manufacturing and operating costs.

 

2


Hardware revenue was $9.1 million, compared with $11.4 million in the prior-year period, reflecting the weakness in the Test & Measurement segment. Supplies revenue was $17.5 million versus $16.4 million in the same period of fiscal 2020. Service/other revenue was $2.8 million, compared with $2.7 million a year earlier.

Fiscal Q4 and FY 2021 Results Summary

Revenue totaled $29.4 million in the fourth quarter of fiscal 2021, compared with $30.5 million in the year-earlier period, with a decline in Test & Measurement revenue partly offset by higher revenue in the Product Identification segment. For the full year, revenue was $116.0 million in fiscal 2021 compared with $133.4 million in fiscal 2020.

Gross profit was $11.0 million, or 37.3% of revenue in the fourth quarter of fiscal 2021, compared with $10.2 million, or 33.6% of revenue, in the same period of fiscal 2020. The increase reflected lower manufacturing costs in the 2021 period. For the full year, gross profit was $41.4 million, or 35.6% of revenue in fiscal 2021, compared with $48.8 million, or 36.5% of revenue, in fiscal 2020.

Operating expenses totaled $9.8 million in the fourth quarter of fiscal 2021, down 17.3% compared with $11.9 million in the fourth quarter of fiscal 2020, reflecting the Company’s cost-reduction actions. For the full year, operating expenses were $38.9 million in fiscal 2021, down 16% compared with $46.3 million in fiscal 2020.

Operating income was $1.1 million in the fourth quarter of fiscal 2021, compared with an operating loss of $1.6 million in the fourth quarter of fiscal 2020. For the full year, operating income was $2.4 million for both fiscal 2021 and 2020.

Net income was $0.8 million, or $0.12 per diluted share, in the fourth quarter of fiscal 2021 compared with a net loss of $1.3 million, or $0.19 per share, in the fourth quarter of fiscal 2020. Net income was $1.3 million, or $0.18 per diluted share, in fiscal 2021 compared with net income of $1.8 million, or $0.24 per diluted share, in fiscal 2020.

Adjusted EBITDA, which the Company defines as earnings before interest, taxes, depreciation, amortization and share-based compensation, was $3.1 million for the fourth quarter of fiscal 2021, compared with $43,000 in the fourth quarter of fiscal 2020. For the full year, Adjusted EBITDA was $10.9 million in fiscal 2021 compared with $10.1 million in fiscal 2020. Adjusted EBITDA is a non-GAAP financial measure explained in greater detail below under “Use of Non-GAAP Financial Measure.” Please refer to the financial reconciliation table included in this news release for a reconciliation of net income (loss) to Adjusted EBITDA for the three and 12 months ended January 31, 2021 and 2020.

Bookings in the fourth quarter of fiscal 2021 were $29.2 million, compared with $36.0 million in the fourth quarter of fiscal 2020, primarily reflecting the decrease in Test & Measurement segment orders. Bookings were $113.6 million in fiscal 2021, compared with $136.3 million in fiscal 2020.

 

3


Backlog as of January 31, 2021 was $22.5 million versus $25.2 million at the end of the fiscal 2020 fourth quarter.

Earnings Conference Call

AstroNova will discuss its fiscal fourth-quarter and full-year 2021 financial results in an investor conference call at 9:00 a.m. ET today. To participate on the conference call, please dial (800) 367-2403 (U.S. and Canada) or (334) 777-6978 (International) approximately 10 minutes prior to the start time and enter confirmation code 2525199.

You can hear a replay of the conference call from 12:00 p.m. ET Thursday, March 25, 2021 until 12:00 p.m. ET on Thursday, April 1, 2021 by dialing (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (International). The passcode is 2525199. A real-time and an archived audio webcast of the call will be available through the “Investors” section of the AstroNova website, https://investors.astronovainc.com.

Use of Non-GAAP Financial Measure

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this news release contains the non-GAAP financial measure Adjusted EBITDA, which AstroNova defines as earnings before interest, taxes, depreciation, amortization and share-based compensation. AstroNova believes that the inclusion of this non-GAAP financial measure helps investors gain a meaningful understanding of changes in the Company’s core operating results, and also can help investors who wish to make comparisons between AstroNova and other companies on both a GAAP and a non-GAAP basis. AstroNova’s management uses Adjusted EBITDA, in addition to GAAP financial measures, as the basis for measuring its core operating performance and comparing such performance to that of prior periods and to the performance of its competitors. Adjusted EBITDA also is used by the Company’s management to assist with their financial and operating decision-making.

About AstroNova

AstroNova, Inc. (NASDAQ: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes, and services a broad range of products that acquire, store, analyze, and present data in multiple formats. The Product Identification segment offers a complete line-up of labeling hardware and supplies, allowing customers to mark, track, and enhance their products’ appearance. The segment is comprised of three business units: QuickLabel®, the industry leader in tabletop digital color label printing; TrojanLabel®, an innovative leader for professional label presses; and GetLabels, the premier supplier of label materials, inks, toners, ribbons, and adhesives, all compatible with the major printer brands. Supported by AstroNova’s customer application experts and technology leadership in printing, material science, and high-speed data processing, customers benefit from an optimized, “total solution” approach. The Test and Measurement segment includes the AstroNova Aerospace business unit, which designs and manufactures flight deck printers, networking hardware, and related accessories serving the world’s aerospace and defense industries with proven advanced airborne technology solutions for the cockpit and the cabin; and the Test and Measurement business unit, which offers a suite of products and services that acquire, record, and analyze electronic signal data from local and networked sensors. AstroNova is a member of the Russell Microcap® Index and the LD Micro Index (INDEXNYSEGIS: LDMICRO). Additional information is available by visiting www.astronovainc.com.

 

4


Forward-Looking Statements

Information included in this news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact but rather reflect our current expectations concerning future events and results. These statements may include the use of the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning the Company’s new credit agreement, the outlook for the aerospace industry, the Company’s product development plans and anticipated financial liquidity, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2020 and subsequent filings AstroNova makes with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this news release.

Contact:

Scott Solomon

Senior Vice President

Sharon Merrill Associates

(857) 383-2409

ALOT@investorrelations.com

 

5


ASTRONOVA, INC.

Condensed Consolidated Statements of Income

In Thousands Except for Per Share Data

(Unaudited)

 

     Three Months Ended     Twelve Months Ended  
     January 31, 2021     January 31, 2020     January 31, 2021     January 31, 2020  

Net Revenue

   $  29,438     $  30,479     $  116,033     $  133,446  

Cost of Revenue

     18,456       20,234       74,673       84,688  

Gross Profit

     10,982       10,245       41,360       48,758  

Total Gross Profit Margin

     37.3     33.6     35.6     36.5

Operating Expenses:

        

Selling & Marketing

     6,267       6,762       23,301       26,884  

Research & Development

     1,361       2,216       6,206       8,084  

General & Administrative

     2,206       2,912       9,420       11,357  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total Operating Expenses

     9,834       11,890       38,927       46,325  

Operating Income (Loss)

     1,148       (1,645     2,433       2,433  

Total Operating Margin

     3.9     -5.4     2.1     1.8

Other Income (Expense) , net

     204       (275     (254     (1,063
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (Loss) Before Taxes

     1,352       (1,920     2,179       1,370  

Income Tax Provision (Benefit)

     516       (572     895       (389
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Income (Loss)

   $ 836     $ (1,348   $ 1,284     $ 1,759  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Income (Loss) per Common Share—Basic

   $ 0.12     $ (0.19   $ 0.18     $ 0.25  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net Income (Loss) per Common Share—Diluted

   $ 0.12     $ (0.19   $ 0.18     $ 0.24  
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted Average Number of Common Shares —Basic

     7,124       7,057       7,104       7,024  

Weighted Average Number of Common Shares —Diluted

     7,261       7,136       7,166       7,238  

 

6


ASTRONOVA, INC.

Balance Sheet

In Thousands

(Unaudited)

 

     January 31, 2021     January 31, 2020  

ASSETS

    

CURRENT ASSETS

    

Cash and Cash Equivalents

   $ 11,439     $ 4,249  

Accounts Receivable, net

     17,415       19,784  

Inventories, net

     30,060       33,925  

Prepaid Expenses and Other Current Assets

     1,807       2,193  
  

 

 

   

 

 

 

Total Current Assets

     60,721       60,151  

PROPERTY, PLANT AND EQUIPMENT

     50,839       48,046  

Less Accumulated Depreciation

     (38,828     (36,778
  

 

 

   

 

 

 

Property, Plant and Equipment, net

     12,011       11,268  

OTHER ASSETS

    

Intangible Assets, net

     21,502       25,383  

Goodwill

     12,806       12,034  

Deferred Tax Assets

     5,941       5,079  

Right of Use Asset

     1,389       1,661  

Other Assets

     1,103       1,088  
  

 

 

   

 

 

 

TOTAL ASSETS

   $  115,473     $  116,664  
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

CURRENT LIABILITIES

    

Accounts Payable

   $ 5,734     $ 4,409  

Accrued Compensation

     2,852       2,700  

Other Liabilities and Accrued Expenses

     3,939       4,711  

Current Portion of Long-Term Debt

     5,326       5,208  

Revolving Credit Facility

     —         6,500  

Current Portion of Royalty Obligation

     2,000       2,000  

Current Liability – Excess Royalty Payment Due

     177       773  

Deferred Revenue

     285       466  

Income Taxes Payable

     655       —    
  

 

 

   

 

 

 

Total Current Liabilities

     20,968       26,767  

NON-CURRENT LIABILITIES

    

Long-Term Debt, net of current portion

     7,109       7,715  

Royalty Obligation, net of current portion

     6,161       8,012  

Long-Term Debt—PPP Loan

     4,422       —    

Lease Liability, net of current portion

     1,065       1,279  

Other Long-Term Liabilities

     681       1,081  

Deferred Tax Liabilities

     384       435  
  

 

 

   

 

 

 

TOTAL LIABILITIES

     40,790       45,289  

SHAREHOLDERS’ EQUITY

    

Common Stock

     521       517  

Additional Paid-in Capital

     58,049       56,130  

Retained Earnings

     50,085       49,298  

Treasury Stock

     (33,588     (33,477

Accumulated Other Comprehensive Loss, net of tax

     (384     (1,093
  

 

 

   

 

 

 

TOTAL SHAREHOLDERS’ EQUITY

     74,683       71,375  
  

 

 

   

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

   $ 115,473     $ 116,664  
  

 

 

   

 

 

 

 

7


ASTRONOVA, INC.

Revenue and Segment Operating Profit

In Thousands

(Unaudited)

 

    Revenue     Segment Operating Profit (Loss)     Revenue     Segment Operating Profit (Loss)  
    Three Months Ended     Three Months Ended     Twelve Months Ended     Twelve Months Ended  
    January 31, 2021     January 31, 2020     January 31, 2021     January 31, 2020     January 31, 2021     January 31, 2020     January 31, 2021     January 31, 2020  

Product Identification

  $  23,361     $  20,632     $  3,072     $ 519     $ 90,268     $ 88,116     $  12,885     $ 7,509  

Test & Measurement

    6,077       9,847       282       748       25,765       45,330       (1,032     6,281  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

  $ 29,438     $ 30,479       3,354       1,267     $  116,033     $  133,446       11,853       13,790  
 

 

 

   

 

 

       

 

 

   

 

 

     

Corporate Expenses

        2,206       2,912           9,420       11,357  
     

 

 

   

 

 

       

 

 

   

 

 

 

Operating Income (Loss)

        1,148       (1,645         2,433       2,433  

Other Income (Expense), net

        204       (275         (254     (1,063
     

 

 

   

 

 

       

 

 

   

 

 

 

Income (Loss) Before Income Taxes

        1,352       (1,920         2,179       1,370  

Income Tax Provision (Benefit)

        516       (572         895       (389
     

 

 

   

 

 

       

 

 

   

 

 

 

Net Income (Loss)

      $ 836     $  (1,348       $ 1,284     $ 1,759  
     

 

 

   

 

 

       

 

 

   

 

 

 

 

8


ASTRONOVA, INC.

Reconciliation of Net Income (Loss) to Adjusted EBITDA

Amounts in Thousands

     (Unaudited)    

 

     Three Months Ended     Twelve Months Ended  
     January 31, 2021      January 31, 2020     January 31, 2021      January 31, 2020  

Net Income (Loss)—GAAP

   $ 836      $  (1,348   $ 1,284      $ 1,759  

Interest Expense

     253        174       955        682  

Income Tax Provision (Benefit)

     516        (572     895        (389

Share-Based Compensation

     132        199       1,819        1,775  

Depreciation/Amortization

     1,412        1,590       5,983        6,284  
  

 

 

    

 

 

   

 

 

    

 

 

 

Adjusted EBITDA

   $  3,149      $ 43     $  10,936      $  10,111  
  

 

 

    

 

 

   

 

 

    

 

 

 

 

9

EX-101.SCH 3 alot-20210323.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 alot-20210323_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 alot-20210323_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g69755g0324172626641.jpg GRAPHIC begin 644 g69755g0324172626641.jpg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d69755d8k_htm.xml IDEA: XBRL DOCUMENT 0000008146 2021-03-23 2021-03-23 false 0000008146 8-K 2021-03-23 ASTRONOVA, INC. RI 0-13200 05-0318215 600 East Greenwich Avenue West Warwick RI 02893 (401) 828-4000 false false false false Common Stock, $0.05 Par Value ALOT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
Mar. 23, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000008146
Document Type 8-K
Document Period End Date Mar. 23, 2021
Entity Registrant Name ASTRONOVA, INC.
Entity Incorporation State Country Code RI
Entity File Number 0-13200
Entity Tax Identification Number 05-0318215
Entity Address, Address Line One 600 East Greenwich Avenue
Entity Address, City or Town West Warwick
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02893
City Area Code (401)
Local Phone Number 828-4000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.05 Par Value
Trading Symbol ALOT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

5(<.&7J/P$ #P" / M " 3P0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " Z/7E2)!Z; MHJT #X 0 &@ @ &H$0 >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " Z/7E299!YDAD! #/ P $P M @ &-$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #7 %$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d69755d8k.htm alot-20210323.xsd alot-20210323_lab.xml alot-20210323_pre.xml d69755dex991.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d69755d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d69755d8k.htm" ] }, "labelLink": { "local": [ "alot-20210323_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "alot-20210323_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "alot-20210323.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "alot", "nsuri": "http://astro-med.com/20210323", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d69755d8k.htm", "contextRef": "duration_2021-03-23_to_2021-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d69755d8k.htm", "contextRef": "duration_2021-03-23_to_2021-03-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://astro-med.com//20210323/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-21-093409-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-093409-xbrl.zip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͈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end